Date: Fri, 11 Jan 2002 05:45:46 -1800 From: WSCHwatch@eudoramail.com To: <Money.in.Motion@pios.library.ohyama.toyama.jp> Subject: WSCH: Baby Pharmaceutical on the Rise T Message-ID: <0000723b1f00$00005805$00006b6e@mx2.eudoramail.com>
next in thread | raw e-mail | index | archive | help
<html><head><meta http-equiv=3DContent-Language content=3Den-us><meta http-= equiv=3DContent-Type content=3D"text/html; charset=3Dwindows-1252"><title>= Investors</title></head><body><div align=3Dcenter><center><table border=3D= 2 cellpadding=3D7 cellspacing=3D0 width=3D57% height=3D1 bordercolor=3D#89= BE65 bordercolordark=3D#000000 bordercolorlight=3D#000000><caption> <= /caption><tr><td width=3D100% height=3D43 valign=3Dtop bgcolor=3D#392B55 b= ordercolordark=3D#FFFFFF bordercolorlight=3D#FFFFFF bordercolor=3D#FFFFFF>= <p align=3Dcenter><b><font face=3DVerdana size=3D5 color=3D#EFEFEF>Emergin= g Growth Stock Alert<br> </font><font face=3DVerdana color=3D#EFEFEF size=3D= 2>Wasatch Pharmaceuticals: A Company on the Rise</font></b></td></tr><tr><= td width=3D100% height=3D372 valign=3Dtop align=3Dleft><br> &n= bsp; <font face=3DVerdana color=3D#3F6028><b>Key Points about = WSCH:</b></font> <ul><li><font face=3DVerdana size=3D2>The products and me= dical therapies developed by WSCH represent possibly the <b>most important= breakthrough</b> in the field of Dermatology in the last fifty years.&nbs= p;<br> <br> </font></li><li><font face=3DVerdana size=3D2>WSCH anticipates= <b>FDA approval</b> on seven over-the-counter products within the next ye= ar, which will provide significant revenue in the retail drug market.<br> = <i><br> </i></font></li><li><font face=3DVerdana size=3D2>WSCH has experie= nced a <b>success rate of 90%</b> during clinical studies, completely elim= inating skin disease from 90% of all patients treated.<br> <br> </font></l= i><li><font face=3DVerdana size=3D2>By year five, WSCH plans to have annua= lized revenue over <b>$525 million</b> and over <b>$125 million in EBIT</b= >. This does not take into account income from OTC products which wi= ll be substantial.<br> <br></font><div align=3Dcenter><table border=3D1 ce= llpadding=3D3 cellspacing=3D0 width=3D83% bordercolorlight=3D#EFEFEF borde= rcolordark=3D#EFEFEF bordercolor=3D#EFEFEF><tr><td width=3D35% bgcolor=3D#= 392B55 bordercolor=3D#392B55 bordercolorlight=3D#392B55 bordercolordark=3D= #392B55><font color=3D#EFEFEF size=3D2 face=3DVerdana>Company Name &n= bsp;</font></td><td width=3D165% valign=3Dtop bgcolor=3D#EFEFEF><b><font c= olor=3D#392B55 size=3D2 face=3DVerdana>Wasatch Pharmaceuticals</font><font= color=3D#392B55 face=3DVerdana size=3D1> </font><font face=3DVerdana size= =3D1 color=3D#3F6028>(OTCBB: WSCH)</font></b></td></tr><tr><td width=3D35%= bgcolor=3D#392B55 bordercolor=3D#392B55 bordercolorlight=3D#392B55 border= colordark=3D#392B55><font color=3D#EFEFEF size=3D2 face=3DVerdana>Current = Price</font></td><td width=3D165% valign=3Dtop bgcolor=3D#EFEFEF><font col= or=3D#392B55 size=3D2 face=3DVerdana>$0.066</font></td></tr><tr><td width=3D= 35% bgcolor=3D#392B55 bordercolor=3D#392B55 bordercolorlight=3D#392B55 bor= dercolordark=3D#392B55><font color=3D#EFEFEF size=3D2 face=3DVerdana>52-We= ek High</font></td><td width=3D165% valign=3Dtop bgcolor=3D#EFEFEF><font c= olor=3D#392B55 size=3D2 face=3DVerdana>$27.50</font></td></tr><tr><td widt= h=3D35% bgcolor=3D#392B55 bordercolor=3D#392B55 bordercolorlight=3D#392B55= bordercolordark=3D#392B55><font color=3D#EFEFEF size=3D2 face=3DVerdana>5= 2-Week Low</font></td><td width=3D165% valign=3Dtop bgcolor=3D#EFEFEF><fon= t color=3D#392B55 size=3D2 face=3DVerdana>$0.065</font></td></tr></table><= /div></li></ul><div align=3Dcenter><table border=3D2 cellpadding=3D7 cells= pacing=3D0 width=3D100% bgcolor=3D#FF0000 bordercolor=3D#FFFFFF bordercolo= rlight=3D#FFFFFF bordercolordark=3D#FFFFFF><tr><td width=3D100% bgcolor=3D= #392B55><p align=3Dcenter><b><font face=3DVerdana size=3D4 color=3D#EFEFEF= >Company Background</font></b></td></tr></table></div><blockquote><p><font= size=3D2 face=3DVerdana>Wasatch Pharmaceutical, Inc. is a fourteen year o= ld company with a record of outstanding achievements in the field of Derma= tology. Under the name of its subsidiary, American Institute of Skin= Care <b>(AISC)</b>, Wasatch has operated two prototype clinics for the la= st five years where the products and medical therapies have been tested an= d proven on hundreds of patients. The Company's activities have been= centered on research in the area of <b>serious skin diseases</b>. A= concurrent discovery and benefit is WSCH's dramatic success in the area o= f skin rejuvenation. Seeing the high growth potential from major fun= ding, WSCH elected to <b>become a public company</b> less than two years a= go.</font></p><p><font size=3D2 face=3DVerdana>Wasatch's major successes i= n the area of skin diseases include: <b><br> <br> Cystic Acne, Eczema= , Seborrhea, Contact Dermatitis, Molluscum, Folliculitis, Acne Rosacea and= less prevalent skin diseases.</b> <br> <br> Interestingly, the= se skin disorders account for more than <b>70% of all business</b> in the = field of dermatology for which there are very few (if any) safe, effective= therapies like those developed by <b>Wasatch.</b><br> <br> Because the th= erapies developed by Wasatch <b>dominate</b> this area of medicine, WSCH h= as elected to market its products via company-owned clinics throughout the= United States. This decision has resulted in the establishment of <= b>two research clinics</b> in Utah for the purpose of implementing procedu= res within the clinics pursuant to testing and confirming the results that= were achieved in past clinical trials. Due to its <b>success rate o= f 90% on hundreds of patients over a five year period</b>, WSCH's clinics = are now on line with insurance providers independent of HMOs. Effort= s to establish Preferred Provider ship status with HMOs are presently bein= g pursued. </font></p></blockquote><div align=3Dcenter><table border=3D= 2 cellpadding=3D7 cellspacing=3D0 width=3D101% bordercolor=3D#FFFFFF borde= rcolorlight=3D#FFFFFF bordercolordark=3D#FFFFFF height=3D44><tr><td width=3D= 100% bgcolor=3D#392B55 height=3D28><p align=3Dcenter><b><font face=3DVerda= na size=3D4 color=3D#EFEFEF>Most Recent WSCH News</font></b></td></tr></ta= ble></div><div align=3Dcenter><table border=3D1 cellpadding=3D7 cellspacin= g=3D0 width=3D83% height=3D382 bgcolor=3D#EFEFEF bordercolorlight=3D#392B5= 5 bordercolordark=3D#392B55 bordercolor=3D#392B55><caption> </caption= ><tr><td width=3D100% height=3D366><h2>Wasatch Pharmaceutical Inc. Announc= es a New Physician Marketing Campaign and Listing On German Stock Exchange= s</h2><p><font face=3DVerdana size=3D2>MURRAY, Utah--(BUSINESS WIRE)--Nov.= 27, 2001--Wasatch Pharmaceutical Inc. (OTCBB:<a href=3Dhttp://finance.yah= oo.com/q?s=3Dwsch.ob&d=3Dt>WSCH</a> - <a href=3Dhttp://biz.yahoo.com/n= /w/wsch.ob.html>news</a>) CEO Gary Heesch announced today a marketing camp= aign directed to physicians. A direct link has been established on a physi= cian recruiting Web site making available therapies for the treatment of c= ystic acne, acne, folliculitis, and skin rejuvenation. Physicians will fin= d the benefits of these treatment therapies by logging on to the <b>"= X Acne" link at <a href=3Dhttp://physicianssearch.com>physicianssearc= h.com</a></b>. This physician search Web site typically receives over <b>2= 00,000 hits per month</b>. Mr. Heesch reminded, "Our treatment therap= y products are also available via the AISC Online Store at <a href=3Dhttp:= //restoremyskin.com>restoremyskin.com</a>.'"</font><p><font face=3DVe= rdana size=3D2>These skin treatment products come in kit form providing a = 90-day supply to patients for the full treatment program. Included in the = kit is an instructional video on the treatment therapy allowing the patien= t to use these products in their home. The therapies, when used as instruc= ted, achieve a <b>success rate of eradication in excess of 90% with no sid= e effects of any consequence</b>. Previously, these therapies and associat= ed products were only available through the two prototype clinics in Utah.= The availability of these products will open the way for family practitio= ners, pediatricians, internists and other primary care physicians to retai= n their patients under their care during the treatment of these common ski= n disorders. <b>The benefit to insurance providers is the potential to sav= e millions of dollars in reimbursement costs by freeing the physician and = the patient from ongoing treatment.</b></font><p><font face=3DVerdana size= =3D2>In the coming year, <u>six additional therapies will be made availabl= e</u> for a broad range of skin disorders that are badly in need of succes= sful therapies.</font><p><font face=3DVerdana size=3D2>Gary Heesch also an= nounced the listing of Wasatch Pharmaceutical stock on the <b>Frankfurt an= d Berlin Exchanges in Germany</b>. Active trading on these exchanges will = take place upon the completion of a research report in Germany. Said Mr. H= eesch, "We feel this is a significant event as Wasatch will gain <b>w= ider exposure</b> as a leader in dermatology and will put <u>buying</u> <u= >pressure on its stock to <b>reflect the true value</b> </u>of a company t= hat has committed years of research and development of products that allow= people with serious skin disorders to live normal and more productive liv= es."</font><p><font size=3D1 face=3DArial><i>There may be forward-loo= king statements in this release. Investors are cautioned that such forward= -looking statements involve risks and uncertainties, including, without li= mitation, continued acceptance of the Company's products, increased levels= of competition, new products introduced by competitors, changes in the ra= tes of subscriber acquisition and retention, and other risks detailed from= time to time in the Company's periodic reports filed with the Securities = and Exchange Commission.</i></font></td></tr></table></div><p align=3Dcent= er><b><i><span style=3D"font-size:10.0pt; font-family:Arial"><o:p></span></i></b></p><div align=3Dcenter><table bord= er=3D2 cellpadding=3D7 cellspacing=3D0 width=3D100% bgcolor=3D#392B55 bord= ercolordark=3D#FFFFFF bordercolorlight=3D#FFFFFF bordercolor=3D#FFFFFF hei= ght=3D51><tr><td width=3D100% height=3D35><p align=3Dcenter><b><font face=3D= Verdana size=3D4 color=3D#EFEFEF>Projections, Objectives, and Statistics</= font></b></td></tr></table></div><p style=3Dmargin-left:.5in><font face=3D= Verdana size=3D2> Over a five year period, AISC (WSCH's subsidiary) p= lans to establish <b>350 clinics in over 100 major population areas</b>.&n= bsp; The company plans to hire over 150 medical doctors for these clinics,= train over 1,000 medical assistants and treat over <b>2,000,000 patients<= /b>. Also by year five, WSCH plans to have annualized over <u>$525 million= in revenue and over $125 million in EBIT</u>. This does not take into acc= ount income from OTC products which will be substantial. </font></p><= blockquote><p><font face=3DVerdana size=3D2> As of 1991, there were = approximately 14 million chronic acne and eczema patients annually in the = United States, with the highest percentage between 18 to 44 years of = age. The actual number of patients with any type of acne is significa= ntly higher. <b>Seven billion dollars is spent annually </b>on derma= tological pharmaceutical products for these disorders. <br> <br>= In 1994, the teen population reached 25 million. During the next d= ecade, it will grow at <b>nearly twice the rate of <br> the overall p= opulation </b>(according to U.S. Census Bureau projections). Acne pat= ients are primarily teenagers, whereas eczema patients range from inf= ants to the elderly.<b><br></b></font></blockquote><div align=3Dcenter><ta= ble border=3D2 cellpadding=3D7 cellspacing=3D0 width=3D100% bgcolor=3D#392= B55 bordercolorlight=3D#FFFFFF bordercolordark=3D#FFFFFF bordercolor=3D#FF= FFFF height=3D45><tr><td width=3D100% height=3D29><p align=3Dcenter><b><fo= nt face=3DVerdana size=3D4 color=3D#EFEFEF>A Look at the Competition</font= ></b></td></tr></table></div><blockquote><p><font face=3DVerdana size=3D2>= Dermatologists are the primary competitors of WSCH's clinics. Dermatologis= ts specialize in the treatment of skin disorders and prescribe medications= to treat the disorder. However, competing products address the <b>s= ymptoms</b> of acne and eczema, <b>not the cause. </b></font></p><p><= font face=3DVerdana size=3D2>The competition's skin care treatments includ= e prescription medications (oral and external use drugs prescribed by derm= atologists and other doctors) and over-the-counter products. <b= r> <br> <b>Several common prescription medications include: </b><br> = 1) E-Mycin for oral and topical use, 2) Cleocin for oral and topical use, = 3) Tetracycline for oral and topical use, and 4) Accutane for oral use onl= y. <br> <b><br> Over-the-counter acne medications include: = ;</b><br> 1) Clearasil and Oxy creams, 2) generic brand creams, 3) medicat= ed pads, and 4) medicated soaps. <br> <br> <u><i>Many of the competit= ion's oral medications have serious side effects.</i></u></font><p><font f= ace=3DVerdana size=3D2>Costs for competing treatments range from $2.50 for= medicated soaps to $200 for Accutane oral medication prescription. = Treatments are on-going. Over time a person can spend an <b>unlimite= d amount of money</b> on such treatments. An example would be someon= e who spent $1,500 for a 22 week program of Accutane which includes blood = testing. Another example would be someone who has had acne for many = years and has spent in excess of $34,000. </font><p><font face=3DVerd= ana size=3D2>At this time there is <b>no known competitor </b>who treats t= he causes of these skin disorders and no competitor can claim a <b>success= rate</b> equal to that of Wasatch's treatments. </font></p></blockqu= ote><div align=3Dcenter><table border=3D2 cellpadding=3D7 cellspacing=3D0 = width=3D100% bgcolor=3D#392B55 bordercolordark=3D#FFFFFF bordercolorlight=3D= #FFFFFF bordercolor=3D#FFFFFF><tr><td width=3D100%><p align=3Dcenter><b><f= ont face=3DVerdana size=3D4 color=3D#EFEFEF>Final Thoughts on WSCH</font><= /b></td></tr></table></div><blockquote><p><font face=3DVerdana size=3D2>Wi= th a proven success rate of 90% in a field that affects so many of our liv= es, Wasatch has clearly positioned itself in a market <b>hungry and desper= ate</b> for successful products and treatment. WSCH has recently exp= anded its marketing presence (as seen in the above press release) and will= continue to aggressively broaden awareness over the near term. The listin= g of <b>WSCH</b> on the German stock exchange is another sign of the compa= ny's credibility and ambitious plans to establish itself as a <b>major glo= bal player</b> in the field of dermatology. <br> <br> WSCH has = taken on a completely different approach. By addressing the causes o= f skin disorders rather than the symptoms, WSCH will help to successfully = eliminate skin disease altogether. Given its <br> <br> 1. Successful = 14-year history and plans for expansion<br> 2. Impressive revenue projecti= ons ($525 million+ annualized by year 5 and $125 million in EBIT)<br>= 3. Virtually unmatched success rate of 90%...<br> <br> ...<b>and so much = more, WSCH will certainly watched by savvy investors for some time to come= .</b><br></font></blockquote></td></tr><tr><td width=3D100% height=3D368 v= align=3Dtop><font color=3D#5F5F5F face=3DVerdana><font size=3D1>DISCLAIMER= : <br> Information within this email contains "forward looking s= tatements" within the meaning of Section 27A of the Securities Act of= 1933 and Section 21B of the Securities Exchange Act of 1934. Any statemen= ts that express or involve discussions with respect to predictions, expect= ations, beliefs, plans, projections, objectives, goals, assumptions or fut= ure events or performance are not statements of historical fact and may be= "forward looking statements."<br> <br> Forward looking statemen= ts are based on expectations, estimates and projections at the time the st= atements are made that involve a number of risks and uncertainties wh= ich could cause actual results or events to differ materially from those p= resently anticipated. Forward looking statements in this action may be ide= ntified through the use of words such as "projects", "fores= ee", "expects</font></font><font face=3DVerdana size=3D1 color=3D= #5F5F5F>"</font><font face=3DVerdana size=3D1 color=3D#5F5F5F>, </fon= t><font face=3DVerdana size=3D1 color=3D#5F5F5F>"</font><font face=3D= Verdana size=3D1 color=3D#5F5F5F>will,</font><font face=3DVerdana size=3D1= color=3D#5F5F5F>"</font><font face=3DVerdana size=3D1 color=3D#5F5F5= F> </font><font face=3DVerdana size=3D1 color=3D#5F5F5F>"</font= ><font face=3DVerdana size=3D1 color=3D#5F5F5F>anticipates,</font><font fa= ce=3DVerdana size=3D1 color=3D#5F5F5F>"</font><font face=3DVerdana si= ze=3D1 color=3D#5F5F5F> </font><font face=3DVerdana size=3D1 color=3D#5F5F= 5F>"</font><font face=3DVerdana size=3D1 color=3D#5F5F5F>estimates,</= font><font face=3DVerdana size=3D1 color=3D#5F5F5F>"</font><font face= =3DVerdana size=3D1 color=3D#5F5F5F> </font><font face=3DVerdana size=3D1 = color=3D#5F5F5F>"</font><font face=3DVerdana size=3D1 color=3D#5F5F5F= >believes,</font><font face=3DVerdana size=3D1 color=3D#5F5F5F>"</fon= t><font face=3DVerdana size=3D1 color=3D#5F5F5F> "understands" o= r that by statements indicating certain actions </font><font face=3DVerdan= a size=3D1 color=3D#5F5F5F>"</font><font face=3DVerdana size=3D1 colo= r=3D#5F5F5F>may,</font><font face=3DVerdana size=3D1 color=3D#5F5F5F>"= ;</font><font face=3DVerdana size=3D1 color=3D#5F5F5F> </font><font face=3D= Verdana size=3D1 color=3D#5F5F5F>"</font><font face=3DVerdana size=3D= 1 color=3D#5F5F5F>could,</font><font face=3DVerdana size=3D1 color=3D#5F5F= 5F>"</font><font face=3DVerdana size=3D1 color=3D#5F5F5F> or </font><= font face=3DVerdana size=3D1 color=3D#5F5F5F>"</font><font face=3DVer= dana size=3D1 color=3D#5F5F5F>might</font><font face=3DVerdana size=3D1 co= lor=3D#5F5F5F>"</font><font face=3DVerdana size=3D1 color=3D#5F5F5F> = occur. All information provided within this email pertaining to inve= sting, stocks, securities must be understood as information provided and n= ot investment advice. Emerging Growth Stock Alert advises all readers and = subscribers to seek advice from a registered professional securities = representative before deciding to trade in stocks featured within this ema= il. None of the material within this report shall be construed as an= y kind of investment advice.<br> <br> In compliance with the Securities Ac= t of 1933, Section17(b), Emerging Growth Stock Alert discloses the receipt= of $40,000 cash from a third party for the publication of this report and= additional<span style=3D"mso-spacerun: yes"> </span>services related= to WSCH. Be aware of an inherent conflict of interest resulting from such= compensation. All factual information in this report was gathe= red from public sources, including but not limited to SEC filings, Company= Press Releases, and the company's website at wasatchpharm.com.<span style= =3D"mso-spacerun: yes"> </span>Emerging Growth Stock Alert believes t= his information to be reliable but can make no guarantee as to its accurac= y or completeness. Use of the material within this email constitutes your = acceptance of these terms.</font><p align=3Dcenter><font face=3DVerdana si= ze=3D1 color=3D#5F5F5F><br> <br> </font><font face=3DVerdana size=3D2>To b= e removed from future mailings, please respond <br> to this email with &qu= ot;Remove" in the subject line</font></p></td></tr></table></center><= /div></body></html> To Unsubscribe: send mail to majordomo@FreeBSD.org with "unsubscribe freebsd-current" in the body of the message
Want to link to this message? Use this URL: <https://mail-archive.FreeBSD.org/cgi/mid.cgi?0000723b1f00$00005805$00006b6e>